Current Report Filing (8-k)
05 4월 2022 - 11:58PM
Edgar (US Regulatory)
0001499785
false
00000
CN
0001499785
2022-03-30
2022-03-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
and Exchange Act of 1934
Date of Report (date of earliest event reported):
March 30, 2022
Tengjun Biotechnology Corp.
(Exact name
of registrant as specified in its charter)
| Nevada |
|
333-169397 |
|
27-3042462 |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
| of incorporation) |
|
|
|
Identification Number) |
East Jinze Road and South Huimin Road, Food
Industry Economic and Technology Development District,
Jinxiang County, Jining City, Shandong Province, China
(Address
of principal executive offices and zip code)
(86) 0537-8711599
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name
or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
| None |
|
None |
|
None |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On March 30, 2022, the board of directors (the
“Board”) of Tengjun Biotechnology Corp. (the “Company”) adopted a resolution, subject to the Company’s shareholder
approval, to increase its authorized capital from 70,000,000 to 200,000,000 shares of its common stock (the “Increase in Authorized
Capital”) by amending and restating the Company’s articles of incorporation.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly
authorized.
| Date: April 5, 2022 |
|
|
| |
|
|
| |
Tengjun Biotechnology Corp. |
| |
|
| |
By: |
/s/ Xianchang Ma |
| |
|
Xianchang Ma |
| |
|
Chief Executive Officer |
2
Tengjun Biotechnology (CE) (USOTC:TJBH)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Tengjun Biotechnology (CE) (USOTC:TJBH)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
